Furthermore, several studies support that SGLT2 inhibitors promote reduction of VAT in patients with T2D, improve hepatic steatosis with reduction in liver fat content in patients with T2D and MASLD, and support positive effects on cardiometabolic biomarkers in patients with T2D suggesting that early administration of SGLT2 inhibitors in patients with T2D and MASLD may be favorable [57–63]. This evidence concerns the gene SLC5A2 and Hepatic steatosis.